Related Experiment Video
Updated: Oct 18, 2025
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
The clinical landscape of chronic graft-versus-host disease management in 2021
Noa G Holtzman1, Steven Z Pavletic1
1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Insights
New therapies are emerging for chronic graft-versus-host disease (cGVHD), a serious complication after stem cell transplants. This review highlights recent advancements in systemic, organ-specific, and topical treatments for cGVHD management.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic graft-versus-host disease (cGVHD) is a significant complication following allogeneic hematopoietic stem cell transplantation.
- It presents with diverse multi-organ involvement, leading to substantial morbidity and mortality.
- Current curative treatments for cGVHD remain limited despite advances in understanding its pathophysiology.
Observation:
- The last decade has seen increased collaborative research and standardized clinical trial criteria.
- These efforts have facilitated the identification of several novel second-line therapies for cGVHD.
- Successful management hinges on a multidisciplinary approach, emphasizing supportive and ancillary care.
Findings:
- This review synthesizes recent developments in cGVHD treatment since the 2014 NIH consensus conference.
- It covers advancements in systemic therapies, organ-specific interventions, and topical treatments.
- New therapeutic strategies aim to improve control and outcomes for cGVHD patients.
Implications:
- The emergence of new therapies offers improved options for managing cGVHD.
- A comprehensive, multidisciplinary approach is crucial for effective cGVHD control.
- Continued research and standardization are vital for advancing cGVHD treatment and patient care.
Abstract:
Chronic graft-versus-host disease (cGVHD) is an important systemic complication of allogeneic haematopoietic stem cell transplantation with heterogeneous, multi-organ involvement that can lead to increased morbidity and mortality. Despite significant advances in understanding the complex pathophysiology driving the disease, curative treatment options remain suboptimal. The past decade, however, has seen much growth in collaborative research efforts and standardization of criteria for clinical trials that have led to discovery of several new second-line therapies in cGVHD. The key to successful cGVHD control and management includes a comprehensive and sustained multidisciplinary effort with emphasis on ancillary and supportive care for these patients. The focus of this review is to summarize the new developments in systemic, organ-specific, and topical treatments in the management of cGVHD that emerged since the 2014 NIH consensus conference.
Related Concept Videos
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:16Kidney Transplant III: Nursing Management
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
01:18Chronic Kidney Disease IV: Nursing Management